报价延迟最少15分钟:2025/07/21 06:53 EDT
盘前时段
|
||||
|
2.61 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.30/-1.25
|
|
企业价值
21.03M
|
| 资产负债 |
|
每股账面净值
2.95
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
1.00M
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 06:53 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product. |
